《用于三阴性乳腺癌治疗的蛋白水解靶向嵌合体的超声可控释放》勘误
Erratum to "Ultrasound Controllable Release of Proteolysis Targeting Chimeras for Triple-Negative Breast Cancer Treatment".
作者信息
He Hongye, Li Feng, Tang Rui, Wu Nianhong, Zhou Ying, Cao Yuting, Wang Can, Wan Li, Zhou Yang, Zhuang Hua, Li Pan
机构信息
Ultrasound Department of the Second Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ultrasound Molecular Imaging, Chongqing 400010, China.
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
出版信息
Biomater Res. 2024 Oct 7;28:0088. doi: 10.34133/bmr.0088. eCollection 2024.
Abstract
[This corrects the article DOI: 10.34133/bmr.0064.].
摘要
[本文更正文章DOI：10.34133/bmr.0064。]
相似文献
1
Erratum to "Ultrasound Controllable Release of Proteolysis Targeting Chimeras for Triple-Negative Breast Cancer Treatment".《用于三阴性乳腺癌治疗的蛋白水解靶向嵌合体的超声可控释放》勘误
Biomater Res. 2024 Oct 7;28:0088. doi: 10.34133/bmr.0088. eCollection 2024.
2
Ultrasound Controllable Release of Proteolysis Targeting Chimeras for Triple-Negative Breast Cancer Treatment.用于三阴性乳腺癌治疗的蛋白水解靶向嵌合体的超声可控释放
Biomater Res. 2024 Aug 13;28:0064. doi: 10.34133/bmr.0064. eCollection 2024.
3
Proteolysis Targeting Chimeras (PROTACs) based on celastrol induce multiple protein degradation for triple-negative breast cancer treatment.基于雷公藤红素的蛋白酶靶向嵌合体（PROTACs）可诱导多种蛋白质降解，用于三阴性乳腺癌的治疗。
Eur J Pharm Sci. 2024 Jan 1;192:106624. doi: 10.1016/j.ejps.2023.106624. Epub 2023 Oct 28.
4
Erratum: Transcriptional Downregulation of miR-4306 serves as a New Therapeutic Target for Triple Negative Breast Cancer: Erratum.勘误：miR-4306的转录下调作为三阴性乳腺癌的新治疗靶点：勘误。
Theranostics. 2023 Feb 9;13(4):1287-1288. doi: 10.7150/thno.82636. eCollection 2023.
5
Erratum: Integrative exploration of genomic profiles for triple negative breast cancer identifies potential drug targets: Erratum.勘误：三阴性乳腺癌基因组图谱的综合探索确定潜在药物靶点：勘误。
Medicine (Baltimore). 2016 Oct 7;95(40):e6564. doi: 10.1097/01.md.0000503499.57465.64. eCollection 2016 Oct.
6
Erratum: Medicine, Volume 95, Issue 23: Erratum.勘误：《医学》，第95卷，第23期：勘误。
Medicine (Baltimore). 2016 Jul 18;95(28):e0916. doi: 10.1097/01.md.0000489580.04709.16. eCollection 2016 Jul.
7
Erratum: Medicine, Volume 95, Issue 24: Erratum.勘误：《医学》，第95卷，第24期：勘误。
Medicine (Baltimore). 2016 Aug 7;95(31):e5074. doi: 10.1097/01.md.0000490009.39850.74. eCollection 2016 Aug.
8
Erratum: Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors.勘误：对三阴性乳腺癌具有选择性活性的Wnt信号通路抑制剂：从噻吩并嘧啶到喹唑啉抑制剂。
Front Pharmacol. 2023 Mar 7;14:1173490. doi: 10.3389/fphar.2023.1173490. eCollection 2023.
9
[Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy].[癌症治疗中蛋白酶靶向嵌合体的靶向递送研究进展]
Sheng Wu Gong Cheng Xue Bao. 2023 Sep 25;39(9):3628-3643. doi: 10.13345/j.cjb.230006.
10
Erratum to epigenetic hypomethylation and upregulation of GD3s in triple negative breast cancer.三阴性乳腺癌中GD3s的表观遗传低甲基化及上调的勘误
Ann Transl Med. 2022 Sep;10(18):1042. doi: 10.21037/atm-2022-48.
本文引用的文献
1
Ultrasound Controllable Release of Proteolysis Targeting Chimeras for Triple-Negative Breast Cancer Treatment.用于三阴性乳腺癌治疗的蛋白水解靶向嵌合体的超声可控释放
Biomater Res. 2024 Aug 13;28:0064. doi: 10.34133/bmr.0064. eCollection 2024.
Zotero 插件